Also from this source

You just read:

Daiichi Sankyo Submits Edoxaban Marketing Authorization Application to the EMA for Once-Daily Use for Stroke Prevention in Atrial Fibrillation and for the Treatment and Prevention of Recurrence of Venous Thromboembolism

News provided by

Daiichi Sankyo

Jan 07, 2014, 11:09 EST